Catalent (CTLT) declines again after cutting guidance

Go back to Catalent (CTLT) declines again after cutting guidance

Catalent (CTLT) cut at JPMorgan on limited near-term visibility

May 22, 2023 12:11 PM EDT

Catalent (NYSE: CTLT) was cut to Neutral from Overweight with a $45 price target, down from $90 per share by JPMorgan analyst Julia Qin on Friday.

Qin told investors that operational fixes are in sight, but accounting questions loom, and they are downgrading the stock... More

Catalent (CTLT) Lowers FY23 Revenue Guidance

May 19, 2023 7:16 AM EDT

Catalent (NYSE: CTLT) Sees FY23 Revenue of $4.25B to $4.35B vs Consensus $4.44B (Prior $4.625B -$4.875B)

Adjust EBITDA $725M to $775MAdj. Net Income $187M to $228M
... More

Catalent (CTLT) to Hold Business Update Call Related to Delay of Third Quarter 2023 Results and Receives NYSE Notice Regarding Late Form 10-Q Filing

May 19, 2023 7:02 AM EDT

Catalent, Inc. (Catalent or the Company) (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that, in light of the circumstances described in the Companys Notification of Late Filing on Form 12b-25 filed on May 11, 2023 (the Form 12b-25) with the Securities and Exchange Commission (the SEC); the Companys ongoing focus on finalizing its financial statements and other disclosures in its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2023 (the Form 10-Q); and completing its quarterly closing processes and procedures, it requires additional time to... More